Supplementary taurine may stabilize atheromatous plaque by antagonizing the activation of metalloproteinases by hypochlorous acid

Medical Hypotheses

Volumn 63, Issue 3, 2004, Pages 414-418

  McCarty, Mark F ^a  

^a Pantox Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMINE DERIVATIVE; HYPOCHLOROUS ACID; MATRIX METALLOPROTEINASE; METALLOPROTEINASE; MYELOPEROXIDASE; SULFINIC ACID DERIVATIVE; TAURINE; THIOL GROUP; TISSUE INHIBITOR OF METALLOPROTEINASE 1; ZINC;

ATHEROMA; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DRUG MECHANISM; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SYNTHESIS; FOAM CELL; HEART INFARCTION; HUMAN; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW;

EID: 3342943466     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2003.10.035     Document Type: Article

References (65)

1. Shah P.K. Role of inflammation and metalloproteinases in plaque disruption and thrombosis. Vasc. Med. 3:1998;199-206
2. Libby P., Schoenbeck U., Mach F., Selwyn A.P., Ganz P. Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization. Am. J. Med. 104:1998;14S-18S
3. Plutzky J. Atherosclerotic plaque rupture: emerging insights and opportunities. Am. J. Cardiol. 84:1999;15J-20J
4. Foo R.S. Present-day investigations cannot adequately determine the risk of acute coronary syndromes. Clin. Lab. 47:1902;257-263
5. George S.J. Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis. Expert Opin. Inv. Drugs. 9:2000;993-1007
6. Shah P.K., Galis Z.S. Matrix metalloproteinase hypothesis of plaque rupture: players keep piling up but questions remain. Circulation. 104:2001;1878-1880
7. Woessner J.F., Nagase H. Matrix metalloproteinases and TIMPs. 2000;Oxford University Press, New York
8. Fu X., Kassim S.Y., Parks W.C., Heinecke J.W. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J. Biol. Chem. 276:2001;41279-41287
9. Van Wart H.E., Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. USA. 87:1990;5578-5582
10. Weiss S.J., Peppin G., Ortiz X., Ragsdale C., Test S.T. Oxidative autoactivation of latent collagenase by human neutrophils. Science. 227:1985;747-749
11. Peppin G.J., Weiss S.J. Activation of the endogenous metalloproteinase, gelatinase, by triggered human neutrophils. Proc. Natl. Acad. Sci. USA. 83:1986;4322-4326
12. Saari H., Sorsa T., Lindy O., Suomalainen K., Halinen S., Konttinen Y.T. Reactive oxygen species as regulators of human neutrophil and fibroblast interstitial collagenases. Int. J. Tissue React. 14:1992;113-120
13. Chatham W.W., Blackburn W.D.J., Heck L.W. Additive enhancement of neutrophil collagenase activity by HOCL and cathepsin G. Biochem. Biophys. Res. Commun. 184:1992;560-567
14. Claesson R., Karlsson M., Zhang Y., Carlsson J. Relative role of chloramines, hypochlorous acid, and proteases in the activation of human polymorphonuclear leukocyte collagenase. J. Leukoc. Biol. 60:1996;598-602
15. Shabani F., McNeil J., Tippett L. The oxidative inactivation of tissue inhibitor of metalloproteinase-1 (TIMP-1) by hypochlorous acid (HOCI) is suppressed by anti-rheumatic drugs. Free Radical Res. 28:1998;115-123
16. Wu S.M., Pizzo S.V. Mechanism of hypochlorite-mediated inactivation of proteinase inhibition by α-2-macroglobulin. Biochemistry. 38:1999;13983-13990
17. Wright C.E., Lin T.T., Lin Y.Y., Sturman J.A., Gaull G.E. Taurine scavenges oxidized chlorine in biological systems. Prog. Clin. Biol. Res. 179:1985;137-147
18. Koyama I., Nakamori K., Nagahama T., Ogasawara M., Nemoto M. The reactivity of taurine with hypochlorous acid and its application for eye drops. Adv. Exp. Med. Biol. 403:1996;9-18
19. Jerlich A., Fritz G., Kharrazi H., Hammel M., Tschabuschnig S., Glatter O., et al. Comparison of HOCI traps with myeloperoxidase inhibitors in prevention of low density lipoprotein oxidation. Biochem. Biophys. Acta. 1481:2000;109-118
20. Davies J.M., Honvitz D.A., Davies K.J. Potential roles of hypochlorous acid and. N -chloroamines in collagen breakdown by phagocytic cells in synovitis Free Radical Biol. Med. 15:1993;637-643
21. Shah S.V., Baricos W.H., Basci A. Degradation of human glomerular basement membrane by stimulated neutrophils. Activation of a metalloproteinase (s) by reactive oxygen metabolites. J. Clin. Invest. 79:1987;25-31
22. Park E., Quinn M.R., Schuller-Levis G. Taurine chloramine attenuates the hydrolytic activity of matrix metalloproteinase-9 in LPS-activated murine peritoneal macrophages. Adv. Exp. Med. Biol. 483:2000;389-398
23. Kontny E., Szczepanska K., Kowalczewski J., Kurowska M., Janicka I., Marcinkiewicz J., et al. The mechanism of taurine chloramine inhibition of cytokine (interleukin-6, interleukin-8) production by rheumatoid arthritis fibroblast-like synoviocytes. Arthritis Rheum. 43:2000;2169-2177
24. Barua M., Liu Y., Quinn M.R. Taurine chloramine inhibits inducible nitric oxide synthase and TNF-α gene expression in activated alveolar macrophages: decreased NF-κB activation and IκB kinase activity. J. Immunol. 167:2001;2275-2281
25. Liu Y., Quinn M.R. Chemokine production by rat alveolar macrophages is inhibited by taurine chloramine. Immunol. Lett. 80:2002;27-32
26. Kanayama A., Inoue J., Sugita-Konishi Y., Shimizu M., Miyamoto Y. Oxidation of IκBα at methionine 45 is one cause of taurine chloramine-induced inhibition of NF-κB activation. J. Biol. Chem. 277:2002;24049-24056
27. Hayes K.C., Pronczuk A., Addesa A.E., Stephan Z.F. Taurine modulates platelet aggregation in cats andhumans. Am. J. Clin. Nutr. 49:1989;1211-1216
28. Franconi F., Bennardini F., Mattana A., Miceli M., Ciuti M., Mian M., et al. Plasma and platelet taurine are reduced in subjects with insulin-dependent diabetes mellitus: effects of taurine supplementation. Am. J. Clin. Nutr. 61:1995;1115-1119
29. Franconi F., Miceli M., Bennardini F., Mattana A., Covarrubias J., Seghieri G. Taurine potentiates the antiaggregatory action of aspirin and indomethacin. Adv. Exp. Med. Biol. 315:1992;181-186
30. Petty M.A., Kintz J., DiFrancesco G.F. The effects of taurine on atherosclerosis development in cholesterol-fed rabbits. Eur. J. Pharmacol. 180:1990;119-127
31. Kondo Y., Murakami S., Oda H., Nagate T. Taurine reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Adv. Exp. Med. Biol. 483:2000;193-202
32. Murakami S., Kondo Y., Sakurai T., Kitajima H., Nagate T. Taurine suppresses development of atherosclerosis in Watanabe heritable hyperlipidemic (WHHL) rabbits. Atherosclerosis. 163:2002;79-87
33. Hazell L.J., Arnold L., Flowers D., Waeg G., Malle E., Stocker R. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J. Clin. Invest. 97:1996;1535-1544
34. Hazen S.L., Heinecke J.W. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J. Clin. Invest. 99:1997;2075-2081
35. Podrez E.A., Abu-Soud H.M., Hazen S.L. Myeloperoxidase-generated oxidants and atherosclerosis. Free Radical Biol. Med. 28:2000;1717-1725
36. Leeuwenburgh C., Rasmussen J.E., Hsu F.F., Mueller D.M., Pennathur S., Heinecke J.W. Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. J. Biol. Chem. 272:1997;3520-3526
37. Hazen S.L., Heinecke J.W. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J. Clin. Invest. 99:1997;2075-2081
38. Hazell L.J., Stocker R. α-Tocopherol does not inhibit hypochlorite-induced oxidation of apolipoprotein B-100 of low-density lipoprotein. FEBS Lett. 414:1997;541-544
39. Carr A.C., Tijerina T., Frei B. Vitamin C protects against and reverses specific hypochlorous acid- and chloramine-dependent modifications of low-density lipoprotein. Biochem. J. 346(Pt 2):2000;491-499
40. Fabjan J.S., Abuja P.M., Schaur R.J., Sevanian A. Hypochlorite induces the formation of LDL (-), a potentially atherogenic low density lipoprotein subspecies. FEBS Lett. 499:2001;69-72
41. Zhang R., Brennan M.L., Fu X., Aviles R.J., Pearce G.L., Penn M.S., et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 286:2001;2136-2142
42. Nikpoor B., Turecki G., Fournier C., Theroux P., Rouleau G.A. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am. Heart J. 142:2001;336-339
43. Azuma J., Takihara K., Awata N., Ohta H., Sawamura A., Harada H., et al. Beneficial effect of taurine on congestive heart failure induced by chronic aortic regurgitation in rabbits. Res. Commun. Chem. Pathol. Pharmacol. 45:1984;261-270
44. Azuma J., Sawamura A., Awata N., Ohta H., Hamaguchi T., Harada H., et al. Therapeutic effect of taurine in congestive heart failure: a double-blind crossover trial. Clin. Cardiol. 8:1985;276-282
45. Azuma J., Sawamura A., Awata N. Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn. Circ. J. 56:1992;95-99
46. Kohashi N., Okabayashi T., Hama J., Katori R. Decreased urinary taurine in essential hypertension. Prog. Clin. Biol. Res. 125:1983;73-87
47. Fujita T., Ando K., Noda H., Ito Y., Sato Y. Effects of increased adrenomedullary activity and taurine in young patients with borderline hypertension. Circulation. 75:1987;525-532
48. Yamori Y., Nara Y., Ikeda K., Mizushima S. Is taurine a preventive nutritional factor of cardiovascular diseases or just a biological marker of nutrition? Adv. Exp. Med. Biol. 403:1996;623-629
49. Nara Y., Yamori Y., Lovenberg W. Effect of dietary taurine on blood pressure in spontaneously hypertensive rats. Biochem. Pharmacol. 27:1978;2689-2692
50. Sato Y., Ogata E., Fujita T. Hypotensive action of taurine in DOCA-salt rats-involvement of sympathoadrenal inhibition and endogenous opiate. Jpn. Circ. J. 55:1991;500-508
51. Ideishi M., Miura S., Sakai T., Sasaguri M., Misumi Y., Arakawa K. Taurine amplifies renal kallikrein and prevents salt-induced hypertension hi Dahl rats. J. Hypertens. 12:1994;653-661
52. Anuradha C.V., Balakrishnan S.D. Taurine attenuates hypertension and improves insulin sensitivity in the fructose-fed rat, an animal model of insulin resistance. Can. J. Physiol. Pharmacol. 77:1999;749-754
53. Harada H., Kitazaki K., Tsujino T., Watari Y., Iwata S., Nonaka H., et al. Oral taurine supplementation prevents the development of ethanol-induced hypertension in rats. Hypertens. Res. 23:2000;277-284
54. McCarty M.F. The reported clinical utility of taurine in ischemic disorders may reflect a down-regulation of neutrophil activation and adhesion. Med. Hypotheses. 53:1999;290-299
55. Pruthi S., Allison T.G., Hensrud D.D. Vitamin E supplementation in the prevention of coronary heart disease. Mayo. Clin. Proc. 76:2001;1131-1136
56. Marchioli R., Schweiger C., Levantesi G., Tavazzi L., Valagussa F. Antioxidant vitamins and prevention of cardiovascular disease: epidemiological and clinical trial data. Lipids. 36(Suppl):1902;S53-S63
57. Yan L.J., Lodge J.K., Traber M.G., Matsugo S., Packer L. Comparison between copper-mediated and hypochlorite-mediated modifications of human low density lipoproteins evaluated by protein carbonyl formation. J. Lipid. Res. 38:1997;992-1001
58. Hazell L.J., Stocker R. α-Tocopherol does not inhibit hypochlorite-induced oxidation of apolipoprotein B-100 of low-density lipoprotein. FEBS Lett. 414:1997;541-544
59. Hazell L.J., Davies M.J., Stocker R. Secondary radicals derived from chloramines of apolipoprotein B-100 contribute to HOCl-induced lipid peroxidation of low-density lipoproteins. Biochem. J. 339(Pt 3):1999;489-495
60. Clark LC, Combs GFJ, Turnbull BW, Slate EH, Chalker DK, Chow J, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group [see comments] [published erratum appears in JAMA 1997 May 21;277(19):1520]. JAMA 1996;276:1957-1963
61. Rana S.K., Sanders T.A. Taurine concentrations in the diet, plasma, urine and breast milk of vegans compared with omnivores. Br. J. Nutr. 56:1986;17-27
62. Laidlaw S.A., Shultz T.D., Cecchino J.T., Kopple J.D. Plasma and urine taurine levels in vegans. Am. J. Clin. Nutr. 47:1988;660-663
63. Seidl R., Peyrl A., Nicham R., Hauser E. A taurine and caffeine-containing drink stimulates cognitive performance and well-being. Amino Acids. 19:2000;635-642
64. Baum M., Weiss M. The influence of a taurine containing drink on cardiac parameters before and after exercise measured by echocardiography. Amino Acids. 20:1902;75-82
65. Alford C., Cox H., Wescott R. The effects of red bull energy drink on human performance and mood. Amino Acids. 21:1902;139-150